JCM
AQST icon

JS Capital Management’s Aquestive Therapeutics AQST Stock Holding History

JS Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-16,000
Closed -$86K – 142
2020
Q4 		$86K Buy
+16,000
New +$95.9K ﹤0.01% 135

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

JS Capital Management's AQST Position: Q1 2021 in Review

JS Capital Management sold out of Aquestive Therapeutics (AQST) in Q1 2021, closing a stake of 16,000 shares — an estimated $86K sold.

JS Capital Management first reported a position in AQST in Q4 2020 and held it in 1 quarter. The position peaked at $86K in Q4 2020. 63 funds tracked by Wall St. Rank hold AQST as of Q1 2021.

  • JS Capital Management reported no remaining Aquestive Therapeutics position as of Q1 2021 after selling out during the quarter.
  • JS Capital Management sold 16,000 Aquestive Therapeutics shares in Q1 2021, an estimated $86K.
  • JS Capital Management first reported a position in Aquestive Therapeutics in Q4 2020 and held it in 1 quarter.
  • JS Capital Management's Aquestive Therapeutics position peaked at $86K in Q4 2020.
  • 63 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2021.

Based on JS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.